The global age-related macular degeneration (AMD) drugs market size touched US$ 10.57 billion in 2024, with expectations of climbing to US$ 11.69 billion in 2025 and hitting US$ 29.04 billion by 2034, driven by a CAGR of 10.66% over the forecast period.
Collaborations between biotech firms, pharma companies, and research institutions accelerate the development and commercialization of next-generation AMD treatments, expanding global market opportunities.
For instance,
Age-Related Macular Degeneration (AMD) medication research and development (R&D) is a multi-phase process that includes preclinical research, clinical trials, and regulatory approval. Before requesting FDA approval, important steps include determining possible drug targets, synthesizing or discovering candidate molecules, conducting preclinical testing in vitro and in vivo, and moving forward through Phase I, II, and III clinical trials to evaluate safety and efficacy.
Organizations: Regeneron Pharmaceuticals, Novartis, Bayer AG, Astellas Pharma, F. Hoffmann-La Rocheetc.
Preclinical research and post-market surveillance are two of the many steps involved in clinical trials and regulatory approvals for medications used to treat AMD (Age-related Macular Degeneration). Clinical trials (phases 1–3), preclinical research, regulatory review (e.g., by the FDA), and post-market are important phases of observation. In recent years, anti-VEGF and anti-complement medications have been approved for the neovascular and geographic atrophy forms of AMD, respectively.
Organizations: regulatory bodies like the FDA (US) and CDSCO (India), CROs (Contract Research Organizations), ethics committees, etc.
Formulation Development
Activities: Converting APIs into stable, safe, and effective formulations (e.g., intravitreal injections, long-acting implants, sustained-release systems).
Organizations Involved: Pharmaceutical Companies: Roche (Susvimo implant), Novartis (Beovu), Regeneron (Eylea HD).
Drug Delivery Innovators: Clearside Biomedical (suprachoroidal injection technology), EyePoint Pharmaceuticals (sustained-release implants).
Final Dose Preparation & Packaging
Activities: Sterile fill-finish operations, vialing, pre-filled syringes, or ocular implant device assembly; compliance with FDA/EMA regulations.
Organizations Involved: Specialized CDMOs: Baxter BioPharma Solutions, Vetter Pharma.
In-house facilities: Bayer, Roche, and Regeneron maintain sterile fill-finish sites.
Distribution & Supply Chain
Activities: Cold chain logistics for biologics, warehousing, and delivery to hospitals and specialty eye clinics.
Organizations Involved: Wholesalers/Distributors: McKesson, AmerisourceBergen, Cardinal Health.
Specialty Distributors: Besse Medical, ASD Healthcare.
Patient Advocacy Groups: BrightFocus Foundation, American Macular Degeneration Foundation (AMDF).
In July 2025, the U.S. Food and Drug Administration announced the fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of Age-related macular degeneration (AMD)-related geographic atrophy (GA). Facilitating the development and accelerating the review of medications to treat serious conditions and address unmet medical needs is the goal of the fast track designation process. The FDA developed this procedure, which addresses a wide range of serious illnesses, to help get important new medications to patients sooner.
In May 2025, A clinical-stage business called Cognition Therapeutics, Inc. is creating medications that treat neurodegenerative diseases. Today released the topline findings from the zervimesine Phase 2 COG2201 'MAGNIFY' trial (CT1812) in adults suffering from dry age-related macular degeneration (dry AMD)-related geographic atrophy (GA). The results show participants receiving zervimesine experienced an average GA lesion growth rate of 28.6% slower, and at 18 months, their lesions were 28.2% smaller in contrast to a placebo. NCT05893537, the MAGNIFY study, was completed after about 100 of the 246 participants were enrolled.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
